BioDelivery Sciences has received a $2.5 million milestone payment for completion of the clinical trial work supporting the dossier and expects to receive an additional milestone payment on approval, followed by revenues from a double digit royalty on net sales. Meda is BioDelivery’s commercialization partner for Bema Fentanyl in North America and Europe.
Mark Sirgo, president and CEO of BioDelivery Sciences, said: “This submission clearly reflects the priority Meda has placed on gaining approval for Bema Fentanyl both in Europe and in the US.”